Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A multicenter, randomized, double-blind, crossover placebo-controlled Phase II study to assess the effect of serelaxin versus placebo on high sensitivity cardiac troponin I (hs-cTnI) release in patients with chronic heart failure after exercise when used in addition to standard of care

    Summary
    EudraCT number
    2015-002673-38
    Trial protocol
    GB   DE  
    Global end of trial date
    11 Jan 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    27 Jan 2018
    First version publication date
    27 Jan 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CRLX030A2211
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02625922
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Novartis Pharma AG
    Sponsor organisation address
    CH-4002, Basel, Switzerland,
    Public contact
    Clinical Disclosure Office, Novartis Pharma AG, +41 613241111,
    Scientific contact
    Clinical Disclosure Office, Novartis Pharma AG, +41 613241111,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    11 Jan 2017
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    11 Jan 2017
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To evaluate the effect of short-term i.v. administration of serelaxin in CHF patients on the geometric mean of high-sensitivity cardiac troponin I (hs-cTnI) concentrations compared to placebo (both in addition to the standard of care) after an exercise testing session.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    05 Feb 2016
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 13
    Country: Number of subjects enrolled
    Germany: 8
    Country: Number of subjects enrolled
    Switzerland: 5
    Worldwide total number of subjects
    26
    EEA total number of subjects
    21
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    4
    From 65 to 84 years
    21
    85 years and over
    1

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    26 subjects were randomized in 11 study sites from 3 countries (Germany, Switzerland, and the United Kingdom).

    Pre-assignment
    Screening details
    Patient selection was to be established by checking through all inclusion/exclusion criteria at screening and randomization.

    Period 1
    Period 1 title
    Overall Period
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Serelaxin-Placebo
    Arm description
    Subjects received serelaxin in Treatment Period 1 and placebo in Treatment Period 2. Serelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion.
    Arm type
    Experimental

    Investigational medicinal product name
    Serelaxin
    Investigational medicinal product code
    Other name
    RLX030
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Matching placebo i.v infusion.

    Arm title
    Placebo-Serelaxin
    Arm description
    Subjects received placebo in Treatment Period 1 and serelaxin in Treatment Period 2. Serelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion.
    Arm type
    Experimental

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Matching placebo i.v infusion.

    Investigational medicinal product name
    Serelaxin
    Investigational medicinal product code
    Other name
    RLX030
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.

    Number of subjects in period 1
    Serelaxin-Placebo Placebo-Serelaxin
    Started
    14
    12
    Completed
    12
    10
    Not completed
    2
    2
         Non-availability of IMP
    1
    1
         Systolic blood pressure < 125 mmHg
    1
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Serelaxin-Placebo
    Reporting group description
    Subjects received serelaxin in Treatment Period 1 and placebo in Treatment Period 2. Serelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion.

    Reporting group title
    Placebo-Serelaxin
    Reporting group description
    Subjects received placebo in Treatment Period 1 and serelaxin in Treatment Period 2. Serelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion.

    Reporting group values
    Serelaxin-Placebo Placebo-Serelaxin Total
    Number of subjects
    14 12 26
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    1 3 4
        From 65-84 years
    12 9 21
        85 years and over
    1 0 1
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    74.7 ( 7.62 ) 66.5 ( 13.89 ) -
    Gender categorical
    Units: Subjects
        Female
    1 2 3
        Male
    13 10 23

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Serelaxin-Placebo
    Reporting group description
    Subjects received serelaxin in Treatment Period 1 and placebo in Treatment Period 2. Serelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion.

    Reporting group title
    Placebo-Serelaxin
    Reporting group description
    Subjects received placebo in Treatment Period 1 and serelaxin in Treatment Period 2. Serelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen. Matching placebo was administered as an i.v infusion.

    Subject analysis set title
    Serelaxin
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants receiving serelaxin in Treatment Period 1 and in Treatment Period 2. Each participant received each of the treatments in randomized order in 2 treatment periods separated by a 15 +/- 1-day washout. Serelaxin was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.

    Subject analysis set title
    Placebo
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants receiving placebo in Treatment Period 1 and in Treatment Period 2. Each participant received each of the treatments in randomized order in 2 treatment periods separated by a 15 +/- 1-day washout. Placebo was administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.

    Primary: Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentration After Exercise Compared to Placebo

    Close Top of page
    End point title
    Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentration After Exercise Compared to Placebo [1]
    End point description
    This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.
    End point type
    Primary
    End point timeframe
    Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15+/- 1)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The primary analysis of mixed model repeated measures was not performed because the validation of the primary endpoint variable hs-cTnI assay (Singulex Erenna®) was not completed because of the early termination of the study and, therefore, hs-cTnI was not analyzed.
    End point values
    Serelaxin-Placebo Placebo-Serelaxin
    Number of subjects analysed
    0 [2]
    0 [3]
    Units: Overall Number of Participants Analyzed
    Notes
    [2] - Primary endpoint variable hs-cTnI assay was not completed due to the early termination of the study.
    [3] - Primary endpoint variable hs-cTnI assay was not completed due to the early termination of the study.
    No statistical analyses for this end point

    Secondary: Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentrations After Exercise Compared to Placebo at 4 and 5 Hours

    Close Top of page
    End point title
    Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentrations After Exercise Compared to Placebo at 4 and 5 Hours
    End point description
    This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.
    End point type
    Secondary
    End point timeframe
    4 and 5 hours after exercise testing session
    End point values
    Serelaxin-Placebo Placebo-Serelaxin
    Number of subjects analysed
    0 [4]
    0 [5]
    Units: Overall Number of Participants Analyzed
    Notes
    [4] - Endpoint variable hs-cTnI assay was not analyzed due to the early termination of the study.
    [5] - Endpoint variable hs-cTnI assay was not analyzed due to the early termination of the study.
    No statistical analyses for this end point

    Secondary: Log-transformed Concentration of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations Compared to Placebo

    Close Top of page
    End point title
    Log-transformed Concentration of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations Compared to Placebo
    End point description
    This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.
    End point type
    Secondary
    End point timeframe
    Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15 +/- 1)
    End point values
    Serelaxin Placebo
    Number of subjects analysed
    26 [6]
    26 [7]
    Units: pg/mL
    arithmetic mean (standard deviation)
        Baseline
    13.5026 ( 0.64893 )
    13.6217 ( 0.60192 )
        132 minutes
    13.5729 ( 0.62057 )
    13.7076 ( 0.61612 )
        180 minutes
    15.5302 ( 0.62107 )
    13.6777 ( 0.61118 )
        240 minutes
    13.5673 ( 0.68419 )
    13.7011 ( 0.58471 )
        300 minutes
    13.6103 ( 0.63614 )
    13.7129 ( 0.57832 )
        360 minutes
    13.6687 ( 0.65735 )
    13.7213 ( 0.57366 )
        420 minutes
    16.6533 ( 0.64776 )
    13.7399 ( 0.57361 )
    Notes
    [6] - The full analysis set (FAS) consisted of all randomized patients.
    [7] - The full analysis set (FAS) consisted of all randomized patients.
    No statistical analyses for this end point

    Secondary: Log-transformed Concentration Values of Heart-type Fatty Acid-binding Protein (H-FABP) Concentrations Compared to Placebo

    Close Top of page
    End point title
    Log-transformed Concentration Values of Heart-type Fatty Acid-binding Protein (H-FABP) Concentrations Compared to Placebo
    End point description
    This cardiac biomarker measurement was obtained to determine plasma concentrations following a cardiac stress test.
    End point type
    Secondary
    End point timeframe
    Baseline, up to 7 hours after the start of an exercise testing session on treatment period 1 (Day 1) and treatment period 2 (Day 15 +/- 1).
    End point values
    Serelaxin Placebo
    Number of subjects analysed
    26 [8]
    26 [9]
    Units: ng/mL
    arithmetic mean (standard deviation)
        Baseline
    8.8256 ( 0.67027 )
    8.8810 ( 0.64372 )
        132 minutes
    8.8644 ( 0.63646 )
    8.8409 ( 0.67261 )
        180 minutes
    8.7897 ( 0.62835 )
    8.7955 ( 0.62729 )
        240 minutes
    8.7718 ( 0.63971 )
    8.8662 ( 0.58565 )
        300 minutes
    8.7309 ( 0.62177 )
    8.7202 ( 0.65890 )
        360 minutes
    8.7692 ( 0.64920 )
    8.8088 ( 0.59672 )
        420 minutes
    8.7669 ( 0.65793 )
    8.7329 ( 0.63139 )
    Notes
    [8] - The full analysis set (FAS) consisted of all randomized patients.
    [9] - The full analysis set (FAS) consisted of all randomized patients.
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse Events are monitored from on or after the time of first administration of study treatment up to 30 days after the last administration were included.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    Serelaxin
    Reporting group description
    Serelaxin

    Reporting group title
    Total
    Reporting group description
    Total

    Reporting group title
    Placebo
    Reporting group description
    Placebo

    Serious adverse events
    Serelaxin Total Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    Musculoskeletal and connective tissue disorders
    Haemarthrosis
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 4%
    Non-serious adverse events
    Serelaxin Total Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    7 / 20 (35.00%)
    12 / 22 (54.55%)
    6 / 20 (30.00%)
    Vascular disorders
    Hypotension
         subjects affected / exposed
    2 / 20 (10.00%)
    2 / 22 (9.09%)
    0 / 20 (0.00%)
         occurrences all number
    2
    2
    0
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    0 / 20 (0.00%)
         occurrences all number
    1
    1
    0
    Headache
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    1
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    0 / 20 (0.00%)
         occurrences all number
    1
    1
    0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    0 / 20 (0.00%)
         occurrences all number
    1
    1
    0
    Inguinal hernia
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    0 / 20 (0.00%)
         occurrences all number
    1
    1
    0
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    0 / 20 (0.00%)
         occurrences all number
    1
    1
    0
    Rash
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    1
    Renal and urinary disorders
    Urinary retention
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    0 / 20 (0.00%)
         occurrences all number
    1
    1
    0
    Infections and infestations
    Rhinitis
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    1
    Urinary tract infection
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    1
    Viral upper respiratory tract infection
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    0 / 20 (0.00%)
         occurrences all number
    1
    1
    0
    Metabolism and nutrition disorders
    Iron deficiency
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    0 / 20 (0.00%)
         occurrences all number
    1
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    27 Oct 2015
    • Updated the assessment of pregnancy according to new information from preclinical studies and the updated Investigator’s Brochure. An additional time point for the pregnancy test was included • Updated the list of exclusion criteria. Exclusion criterion 2 was removed because the patient population was defined as stable based on inclusion criterion 3 and exclusion criterion 6 • Clarified that the Data Monitoring Committee could not terminate the study independently, but could only issue a recommendation to the Sponsor • Provided clarification on the reporting of AEs during the study • Improved the clarity of the description and graphic representation of the Borg CR10 scale and the echocardiography
    20 Dec 2016
    • Adjusted inclusion criterion 4 and defined left ventricular ejection fraction < 50% according to the updated heart failure guidelines of the European Society of Cardiology • Adjusted inclusion criterion 5 to NT-proBNP > 250 ng/L • Adjusted exclusion criterion 14 to exclude patients with a history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a life expectancy less than 1 year • Removed exclusion criterion 4 and accounted for the fact that the primary purpose of the Screening exercise test was to calculate a workload that would stress the patient but allowed them to complete the 12-minute exercise at Treatment Periods 1 and 2. Therefore, maximum capacity threshold of VCO2/VO2 > 1.05 was not to be an exclusion criterion per se • Updated exclusion criterion 17 to match the description of highly effective contraception methods in the current template

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The study was terminated early by Novartis, 19-Apr-2017. Because of the early termination of the study, the validation of the hs-cTnI assay was not completed and the primary efficacy endpoint was not analyzed.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:14:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA